The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Regeneron Plans Early Summer Trials for New Antibodies Against Coronavirus

Regeneron Plans Early Summer Trials for New Antibodies Against Coronavirus

March 18, 2020 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Regeneron Pharmaceuticals Inc. said on Tuesday it had identified hundreds of antibodies that could treat or prevent the coronavirus (COVID-19) and was preparing to begin clinical trials by early summer, sending the drugmaker’s shares up 12%.

You Might Also Like
  • Sanofi, Regeneron Begin Testing Arthritis Drug as Coronavirus Treatment
  • Sanofi, Regeneron Expand Testing of Potential Coronavirus Treatment
  • Data on Arthritis Drug to Treat Coronavirus Could Come within Weeks

The company will select the top two antibodies to develop a “cocktail” treatment and scale up its manufacturing to be able to produce 200,000 doses per month by the end of summer.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

At least a dozen other drugmakers are currently working on vaccines, antivirals and other treatments to help those infected with the fast-spreading virus, with some antivirals already being used in trials.

Regeneron has a far more robust history of drug development for pandemics, says Oppenheimer analyst Hartaj Singh, noting that during the Ebola outbreak, the U.S. drugmaker’s antibody cocktail demonstrated the greatest effect.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“It seems acute treatments will be needed for hundreds of thousands’ of cases, and there could recurring outbreaks in the future … investors are now ascribing greater value to Regeneron stock for this,” he adds.

Pfizer Inc has agreed to co-develop a vaccine with German drugmaker BioNTech SE as well as develop antiviral treatments that could potentially be used with Gilead Sciences Inc’s antiviral called remdesivir against the coronavirus.

Johnson & Johnson and Sanofi have also teamed up with a U.S. government agency to develop virus vaccine candidates.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Drug developer Moderna Inc., which dosed its first patient with its experimental vaccine on Monday, has made the most headway among companies engaged in coronavirus vaccine development efforts.

“Regeneron is arguably the most efficient antibody developer in the biopharma industry and should deserve a higher valuation for its strong innovation capability,” SVB Leerink analyst Geoffrey Porges says.

The company is also considering testing whether its antibody cocktail could be used along with the vaccines in development, spokeswoman Alexandra Bowie tells Reuters.

“There’s a lot of things racing towards the finish line, all at once. It’s yet to be seen what the exact combination would be,” Bowie adds.

The efforts are a part of its partnership with the U.S. Department of Health and Human Services. Regeneron also said it was working with the U.S. Biomedical Advanced Research and Defense Authority to its increase manufacturing capacity.

In addition to the development of the antibody cocktail, the drugmaker is testing its rheumatoid arthritis drug, Kevzara (sarilumab), with partner Sanofi against the virus.

Filed Under: Drug Updates Tagged With: Antibodies, coronavirus, COVID-19

You Might Also Like:
  • Sanofi, Regeneron Begin Testing Arthritis Drug as Coronavirus Treatment
  • Sanofi, Regeneron Expand Testing of Potential Coronavirus Treatment
  • Data on Arthritis Drug to Treat Coronavirus Could Come within Weeks
  • Sanofi Can Produce Millions of Doses of HCQ, Potential Coronavirus Drug

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)